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Dietary gammalinolenic acid (GLA), a potent inhibitor of 5-lipoxygenase (5-LOX) and suppressor of
leukotriene B4 (LTB4), can attenuate the clinical course of rheumatoid arthritics, with negligible side
effects. Since Zileuton, also an inhibitor of 5-LOX, attenuates asthma but with an undesirable side
effect, we investigated whether dietary GLAwould suppress biosynthesis of PMN-LTB4 isolated from
asthma patients and attenuate asthma. Twenty-four mild-moderate asthma patients (16–75 years) were
randomized to receive either 2.0g daily GLA (borage oil) or corn oil (placebo) for 12 months. Blood
drawn at 3 months intervals was used to prepare sera for fatty acid analysis, PMNs for determining
phospholipid fatty acids and for LTB4 generation. Patients were monitored by daily asthma scores,
pulmonary function, and exhaled NO. Ingestion of daily GLA (i) increased DGLA (GLA metabolite) in
PMN-phospholipids; (ii) increased generation of PMN-15-HETrE (5-LOX metabolite of DGLA).
Increased PMN-DGLA/15-HETrE paralleled the decreased PMN generation of proinﬂammatory LTB4.
However, the suppression of PMN-LTB4 did not reveal statistically signiﬁcant suppression of the
asthma scores evaluated. Nonetheless, the study demonstrated dietary fatty acid modulation of
endogenous inﬂammatory mediators without side effects and thus warrant further explorations into the
roles of GLA at higher doses, leukotrienes and asthma.
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INTRODUCTION
Gamma-linolenic acid (18:3n-6) is relatively present in
large amounts in the plant seed oils of borage (18–26%
GLA), black currant (15–20%), and evening primrose
(7–10% GLA), as well as in fungal oil (23–26%). The
triacylglycerol stereospeciﬁc position of GLA varies with
the source of the oils and this is important in establishing
their relative efﬁcacies. For instance, GLA is concentrated
in the sn-3 position of the glycerol bridge of the triacyl-
glycerol in evening primrose and black currant seed oil. In
contrast, GLA is concentrated in the sn-2 position of the
glycerolbridgeinborageoilsandinthesn-2/sn-3positions
of fungal oil (Lawson and Hughes, 1988).
In both humans and rodents, only a small fraction of
the DGLA resulting from the elongation of GLA is
converted by the D5 desaturase to arachidonic acid
(Stone et al., 1979; Ziboh and Fletcher, 1992; Johnson
et al., 1997). This minor conversion is due to the low
activity of D5 desaturase in most tissues, thus reducing
the concerns that dietary GLA/DGLA would contribute
to the excessive accumulation of arachidonic acid and
consequently the generation of pro-inﬂammatory meta-
bolites such as LTB4, LTC4 and LTD4 (Zurier et al.,
1996; Johnson et al., 1997). The preceding reports
indicate that in many tissues and cell-types, DGLA, but
not arachidonic acid, is what accumulates in tissues and
cells after GLA supplementation in the diet. The
accumulated DGLA, is oxygenated via the cyclo-
oxygenase pathway to prostaglandin of the 1-series
(PGE1) and via the 15-lipoxygenase (15-LOX) path-
way to 15(S)-hydroxyeicosatrienoic acid (15-HETrE)
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of DGLA (PGE1 and 15-HETrE) have been reported to
exert biological and clinical effects notably the
suppression of acute and chronic inﬂammation in a
variety of systems and disease conditions. In addition,
DGLA can compete with arachidonic acid for
cyclooxygenase, thus reducing the production of
prostaglandin of the 2-series (PGE2). Similarly, DGLA
is metabolized by the 15-LOX to 15-HETrE which is a
potent inhibitor of the synthesis of the pro-inﬂammatory
mediators LTB4, LTC4 and LTD4 from arachidonic acid
via the 5-LOX pathway. Interestingly, 15-HETrE has
been shown to markedly inhibit LTB4 generation from
arachidonic acid by rat basophilic leukemia (RBL-I)
cells in vitro (Vanderhoek et al., 1980; Miller et al.,
1988). Similarly, hamsters fed GLA-containing oil
revealed signiﬁcantly elevated levels of 15-HETrE in
vivo in the hamster lung which paralleled greatly
reduced LTB4 generation by PMN-inﬁltrated hamster
lung (Ziboh et al., 1997).
Promising therapeutic reports have also emerged after
dietary GLA supplementation in patients with rheumatoid
arthritis (RA) (Leventhal et al., 1993). Asthma on the
other hand is characterized by variable and reversible
airﬂow obstruction and by bronchial hyperresponsiveness,
as well as excessive airway narrowing in response to a
variety of apparently unrelated stimuli. Although contrac-
tion of the airway smooth muscle has been emphasized as
an important mechanism of asthmatic airway obstruction,
it is now recognized that edema of the airway wall
resulting from microvascular leakage, cellular inﬁltration
and luminal obstruction with plasma exudation, cellular
debris and airway secretions are all contributory.
Inﬂammation in the airway wall is therefore a prominent
feature of fatal asthma attack (Dunnill, 1960; Glynn and
Michaels, 1960). There is abundant experimental evidence
that inﬂammation is also present in mild asthma and is
related to bronchial hyperresponsiveness (Chung, 1986), a
characteristic feature of asthma (Boushey et al., 1980).
The pathological changes are therefore likely to include
the release of inﬂammatory mediators such as leuko-
trienes. Therefore, we began a prospective double blind
study designed to address whether dietary supplement
GLA alters the leukotriene proﬁle and the clinical readouts
of patients with asthma.
PATIENTS AND METHODS
Study Design
This is a 12-month, randomized, double-blind comparison
of dietary supplementation of gammalinolenic acid
(GLA)-containing oil (borage oil) to placebo (corn oil)
in patients with asthma. The protocol was reviewed and
approved by the Committee for the Protection of Human
Subjects in Research at the University of California
School of Medicine, Davis. Written informed consent was
obtained from each patient. Patients were eligible to
participate in the study if their asthma condition satisﬁed
the criteria of steps 2 (mild persistent) and 3 (moderate
persistent) of the Expert Panel Report 2: Guidelines for the
Diagnosis and Management of Asthma (1997). Approxi-
mately 80 adult patients were screened, of which 54 met
the criteria for inclusion and whose data is presented
herein. These included a total of 11 male and 43 female
patients. Of these, the average age of male subjects in the
borage group was 52 with a range of 16–71, compared to
the average age of male subjects in the control group of 53,
with a range of 44–62. The average age offemale subjects
in the borage group was 42, with a range of 18–70,
compared to the average age of female subjects in the
control group of 45, with a range of 28–69.
Dietary Protocol
Patients 16–75 years whowere deemed eligible according
to the above criteria were randomly assigned to receive
either GLA (as borage oil) or placebo (as corn oil). Each
borage capsule contained approximately 500mg of GLA
plus 13 IU of D-a-tocopherol (vitamin E) to minimize
oxidation. Similar amount of D-a-tocopherol was
contained in the corn oil capsule. The total daily dose to
each participant (two capsules two times daily with meals)
provided 2.0g of gammalinoleic acid per day. Placebo
capsules which contained corn oil were identical in
appearance and size and were taken according to the same
schedule. The patients were instructed to remain on their
regular medications, have serial clinical evaluation, count
the number of any returned capsules, and provide blood
for isolation of PMNs and fatty acid analysis
Clinical Protocol
Measurement of FEV1
At the baseline evaluation, patients underwent complete
history and physical examination with particular emphasis
on asthma severity based on NAEPP II guidelines. Patients
also underwent measurement of FVC, FEV1 and peak ﬂow
measurements in addition to being provided the Juniper
Quality of Life Questionnaire. Daily wheezing scores and
use of rescue medication was also quantitated.
Exhaled NO Assay
Measurements of exhaled NO was performed using a
restricted exhaled breath, off-line technique (Recommen-
dations for Standardized Procedures for the Online and
Ofﬂine Measurement of Exhaled Lower Respiratory Nitric
Oxide and Nasal Nitric Oxide in Adults and Children,
1999) with an effective ﬂow rate of 100ml/s. NO levels
were measured in triplicate for each patient and time point
using a chemiluminescence analyzer (Sievers Instruments,
Boulder, CO, USA). Patients returned every 3 months for
repeat evaluation.
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Blood was obtained by venipuncture. One portion of the
blood was collected in heparinized tubes and used to
prepare serum for fatty acids analysis. Typically, each
100ml serum sample in a conical tube was extracted with
4ml of CHCl3:CH3OH (2:1, v/v) and 0.8ml 0.1M KCl to
obtain total lipids. The mixturewas vortexed for 1min and
thencentrifugedat600gfor20minat48C.Thelowerorga-
nic phase was collected and a known concentration of
heptadecanoate was added as an internal standard and both
dried under nitrogen gas. The extracted serum total lipids
were transmethylated in 6% methanolic HCl and the
resulting fatty acid methyl esters extracted into petroleum
ether and dried under nitrogen gas. The residue was dis-
solved in dichloromethane and injected into a gas-liquid-
chromatographic instrument. The gas-chromatographic
instrument used (model GC-17A, Shimadzu, Pleasanton,
CA) was equipped with a DB-225 fused silica capillary
column (50% cyanopropylphenyl, 0.15mm ﬁlm thickness,
30m £ 0.25mm id; J&W Scientiﬁc, Rancho Cordova,
CA). Hydrogen (36cm/s) was used as the carrier gas, the
oven was run isothermally at 2108C, and the detection was
performed with a ﬂame-ionization detector (FID).
Preparation of PMNs
The other portion of the whole blood obtained by
veniculture was collected in vacutainer tubes containing
EDTA. Neutrophils were isolated according to the
instructions provided by the commercial kit of Robbins
Scientiﬁc Corp. (Sunnyvale, CA) for the isolation of
human neutrophils. Brieﬂy, the EDTA-anticoagulated
blood, (3.5ml) was layered carefully over 3.8ml of the
PMN medium (metrizoate, 13.8%, w/v:dextran, 8.0%
w/v) in a 10ml centrifuge and then centrifuged at 500g for
35min in a swing out rotor at room temperature. After
centrifugation the middle band in the upright tube, which
comprised mostly of PMNs was removed with pasteur
pipette. The removed PMN cells were diluted with equal
amount of 0.5 NaCl and then transferred to a 10ml tube.
The tube was ﬁlled with 0.9% saline and then centrifuged
at 40g for 10min at room temperature to remove any
contaminating red cell.
Analysis of PMN Leukotriene B4
The puriﬁed PMNs were resuspended in Hank’s balanced-
salt solution (HBSS) which contained no calcium
chloride, magnesium chloride or magnesium sulfate
(Gibco, Grand Island, NY) and then used for assays.
Five hundred microliters of the neutrophil suspension
(1 £ 10
7 cells) in Ca
2þ-free HBSS were added to ﬁve-
hundred microliter of HBSS buffer containing 1.6mM
Ca
2þ to bring the ﬁnal Ca
2þ concentration to 0.8mM. The
neutrophil suspension was preincubated at 378C for
10min. The activation of the cells was initiated by
the addition of 5mlo fC a
2þ ionophore (A23187)
(previously dissolved in DMSO and diluted in Ca
2þ-free
HBSS). The ﬁnal Ca
2þ ionophore concentration was
2mM, and the ﬁnal DMSO concentration was 0.1% (v/v).
The mixture was incubated at 378C for an additional
10min. The reaction was stopped by rapid cooling on ice
at 48C and immediately followed by centrifugation at 600g
at 48C for 10min. The supernatant was removed and
acidiﬁed to pH 3.0 with 9% formic acid in a drop-wise
manner to precipitate out the proteins. The acidiﬁed
extract was extracted with 10ml of CHCl3:CH3OH (2:1,
v/v), and 250ng prostaglandin B2 (PGB2) was added as an
internal standard for quantiﬁcation of LTB4. The lipid
mixture was extracted by vortexing for 1min and then
centrifuged at 600g for 10min at 48C. The lower organic
phase was collected and evaporated in a rota-vapor and the
residue suspended in 100% ethanol and stored at 2208C
until analyzed by HPLC. The HPLC system used
consisted of a Beckman System Gold 125 Solvent Module
pump, a 5-mmC 18 Hypersil
w ODS RP-HPLC columns
(4.6 £ 250mm) (ThermoHypersil, Bellefonte, PA), and a
Beckman Gold System 168 Detector with an on-line diode
array scan. Each column was eluted isocratically for
60min at a ﬂow rate of 1.0ml/min with the mobile phase
of acetonitrile/methanol/water/acetic acid (29:19:52:1 by
volume). The pH of the eluting mobile phase was adjusted
to 5.6 with 1.0M NaOH which resolves the leukotrienes.
Absorbance was continually monitored at 280nm during
elution. Additional identiﬁcation of Ca
2þ ionophore-
induced PMN generated products was by characteristic
ultraviolet absorbance and comparison with the authentic
LTB4 as reported previously (Johnson et al., 1997).
Quantitation of generated LTB4 was determined by using
authentic standard LTB4 obtained from Cayman Chemi-
cals, Ann Arbor, MI.
Analysis of PMN Phospholipid Fatty Acids
A portion of the isolated PMNs were extracted with Folch
mixture (CHCl3:CH3OH 2:1, v/v), dried under nitrogen
gas and then applied to thin layer chromatographic (TLC)
plates coated with Silica Gel G (0.25mm thickness)
(Merck, Darmstadt, Germany). The plates were developed
in the solvent system: chloroform/methanol/acetic acid/
water 90:8:1:0.8, by volume. The band representing total
phospholipids on the TLC plates was ﬁrst sprayed with
0.2% 20,70-dichloroﬂuorescein in ethanol and then
visualized under ultraviolet light. The TLC band which
correlated with total phospholipid standard was scraped
off the plate and then eluted with chloroform/methanol
(2:1, v/v). An internal standard, heptadecanoate, was
added to the mixture and again dried. The eluted total
phospholipids were transmethylated in 6% methanolic
HCl, and the resulting fatty acid methyl esters were
extracted with petroleum ether and dried under nitrogen
gas. The mixture of fatty acids was separated and
quantitated in a Shidmadzu model GC-17A gas chro-
matograph as previously described for serum fatty acids
(Ziboh and Fletcher, 1992).
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Fatty Acid Proﬁle in the Dietary Borage Oil and Corn
Oil
Aliquots of 10ml from each of the capsules containing
either borage oil or corn oil was extracted ﬁrst with
CHCl3:CH3OH (2:1, v/v) and taken to dryness under
nitrogengas.Thetransmethylationandpreparationoffatty
acidmethylestersareasdescribedinthe“Method”section.
Table I illustrates the fatty acid proﬁles in the dietary
capsules. The major polyunsaturated fatty acid (PUFA) in
the borage capsule was GLA (18:3n-6) whereas the major
PUFA in the placebo (corn oil) was linoleic acid (LA,
18:2n-6). Arachidonic acid was negligible in both dietary
oils.
Fatty Acid Proﬁle in the Sera of Patients
The fatty acid proﬁle of both the placebo (corn oil) and the
experimental (borage oil) groups are shown in Table II.
The data show serum fatty acid proﬁles at 3 month
intervals over the 12 months of the study. There was a
statistically signiﬁcant increase in GLA and DGLA in
particular, during the 3, 6 and 12-month evaluations in the
patients ingesting GLA-containing borage oil when
compared to the placebo (corn oil group). There was a
minor but insigniﬁcant elevation of AA in both groups
over the months of study.
Fatty Acid Proﬁle in Neutrophil Phospholipids
To determine whether or not the dietary intake of GLA
does exert attenuating effect on neutrophil generation of
proinﬂammatory LTB4, we determined the fatty acid
proﬁle of the isolated neutrophils as described in the
“Methods” section. The data shown in Table III revealed
a statistically increased incorporation of GLA/DGLA
into total PMN phospholipids of patients who ingested
GLA-containing borage oil at the 6th and 12th months
were compared to the placebo corn oil group. Of
particular note was the statistically signiﬁcant ðp ,
0:05Þ suppression of AA incorporation into the PMN
phospholipids of the patients who ingested GLA-
containing oil when compared to the placebo corn oil
group. This ﬁnding is in contrast to the AA proﬁle in the
serum and also cautions using plasma/serum fatty acids
alone (Table II) as the ﬁnal determinant of fatty acids
levels in the tissues. This ﬁnding suggests that whereas
there is an active elongase activity in the PMNs that
converted GLA to DGLA, there is reduced D5
desaturase activity for conversion of DGLA to AA.
This is consistent with a previous reported in vitro
metabolism of GLA in PMN (Chilton et al., 1996). The
mechanism of AA suppression in the GLA-fed group is
unclear. However, the ﬁnding does imply that increased
DGLA could result in its metabolism in vivo to
metabolites that inhibit PMN-induced generation of
proinﬂammatory LTB4.
TABLE I Fatty acid composition of dietary capsules
Fatty acid
Borage oil (mg/100mg
total fatty acids)
Corn oil (mg/100mg
total fatty acids)
16:0 6.82 9.32
18:0 2.72 2.69
18:1n-9 10.13 25.02
18:2n-6 23.13 60.92
18:3n-6 (GLA) 45.86 –
20:3n-6 (DGLA) ––
20:4n-6 (AA) ––
18:3n-3 0.47 1.75
20:5n-3 ––
22:6n-3 ––
Details of transmethylation and preparations of fatty acid methyl esters are
described in the “Method” section. The number after “n” indicates the number of
carbon atoms from the methyl end of the acyl chain to the nearest double bond.
Values are expressed as percentage of total fatty acids for corn oil (100%), or
borage oil (100%). The abbreviations represent: GLA, gammalinolenic acid;
DGLA, dihomogammalinolenic acid; AA, arachidonic acid.
TABLE II Time-dependent inﬂuence of dietary supplimentation with corn oil and borage oil on patients’ serum unsaturated fatty acids level
UFA Patients
Basal month 0
(mol% ^ SEM)
Month 3
(mol% ^ SEM)
Month 6
(mol% ^ SEM)
Month 12
(mol% ^ SEM)
18:1n-9 C 21.1 ^ 1.1 19.4 ^ 0.8 21.1 ^ 0.6 21.2 ^ 1.5
B 23.3 ^ 0.8 21.6 ^ 0.7 20.5 ^ 0.8 21.5 ^ 0.8
18:2n-6 C 29.3 ^ 1.1 32.1 ^ 0.8 32.1 ^ 1.3 31.6 ^ 2.3
B 28.1 ^ 1.1 27.5 ^ 0.8 27.9 ^ 0.7 27.2 ^ 0.7
18:3n-6 (GLA) C 0.5 ^ 0.1 0.5 ^ 0.1 0.5 ^ 0.1 0.4 ^ 0.1
B 0.5 ^ 0.1 1.2* ^ 0.1 1.1* ^ 0.1 1.2* ^ 0.1
20:3n-6 (DGLA) C 1.3 ^ 0.1 1.4 ^ 0.1 1.4 ^ 0.1 1.4 ^ 0.2
B 1.1 ^ 0.1 2.4* ^ 0.2 2.3* ^ 0.3 2.5* ^ 0.2
20:4n-6 (AA) C 5.9 ^ 0.5 6.5 ^ 0.4 6.6 ^ 0.3 7.0 ^ 0.8
B 5.3 ^ 0.4 6.9 ^ 0.4 7.0 ^ 0.4 7.6 ^ 0.4
18:3n-3 C 0.8 ^ 0.1 0.7 ^ 0.1 0.8 ^ 0.1 0.7 ^ 0.1
B 0.8 ^ 0.1 0.7 ^ 0.1 0.8 ^ 0.1 0.7 ^ 0.1
20:5n-3 C 0.8 ^ 0.2 0.8 ^ 0.2 0.7 ^ 0.2 0.6 ^ 0.3
B 0.5 ^ 0.1 0.5 ^ 0.1 0.5 ^ 0.1 0.5 ^ 0.1
22:6n-3 C 1.4 ^ 0.2 1.4 ^ 0.2 1.4 ^ 0.2 1.5 ^ 0.3
B 1.2 ^ 0.2 1.2 ^ 0.2 1.3 ^ 0.1 1.3 ^ 0.1
Details of transmethylation and preparations of fatty acid methyl esters are described in the “Method” section. The number after “n” indicates the number of carbon atoms
from the methyl end of the acyl chain to the nearest double bond. Values are expressed as mol% of total serum fatty acids ^ SEM. The “number” of patients on C (Corn oil) is
11; The “number” of patients on B (Borage Oil) is 19. Values with * are signiﬁcantly different (p , 0.05).
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PMN Biosynthesis of LTB4
To delineate whether the increased DGLA in PMNs would
exert effect on Ca
2þ ionophore stimulated isolated PMNs,
we incubated the isolated PMNs from both the GLA-
supplemented group and the corn oil supplemented group
with Ca
2þ ionophore. Our data, as shown in Fig. 1
revealed a statistically signiﬁcant ðp , 0:05Þ time-
dependent suppression of PMN-LTB4 generation by
dietary supplementation of GLA-containing borage oil at
6 and 12 months. In contrast, the PMN generation of LTB4
in the placebo corn oil supplemented group revealed
negligible alteration (data not shown). This ﬁnding does
demonstrate that a relationship exists between the length
of time of dietary intake of GLA-containing borage oil and
suppression of PMN capability to biosynthesize LTB4.
The data in Fig. 2 reveals the relationship of PMN
phospholipid DGLA (A) and PMN LTB4 (B) at the 12th
month, the end of the dietary study. Speciﬁcally after 12
months of dietary borage supplementation, the data in
Fig. 2 revealed that increased incorporation of DGLA into
PMN phospholipids (Fig. 2A) paralleled the suppression
of Ca
2þ ionophore activated PMN generation of LTB4
(Fig. 2B), indicating more accumulation of DGLA in the
PMN exerts its effect via the attenuation of PMN
generation of LTB4.
Clinical Responses
Mixed model analysis of variance (ANOVA) methods
were used to model the outcomes of FEV1, peak ﬂow,
“wheezing score”, and “rescue usage”, with the subjects
TABLE III Time-dependent inﬂuence of dietary supplementation with corn oil and borage oil on patients’ PMN—total phospholipid unsaturated fatty
acids level
UFA Patients
Basal month 0
(mg/100mg Total
Phospholipid ^ SEM)
Month 3
(mg/100mg Total
Phospholipid ^ SEM)
Month 6
(mg/100mg Total
Phospholipid ^ SEM)
Month 12
(mg/100mg Total
Phospholipid ^ SEM)
18:1n-9 C 10.4 ^ 1.1 10.6 ^ 1.1 10.1 ^ 1.0 11.3 ^ 1.2
B 11.4 ^ 1.1 10.9 ^ 1.0 11.2 ^ 0.7 11.4 ^ 0.8
18:2n-6 C 4.1 ^ 0.5 4.5 ^ 0.7 4.4 ^ 1.3 4.6 ^ 0.7
B 4.3 ^ 0.6 5.0 ^ 0.5 5.1 ^ 0.5 4.8 ^ 0.5
18:3n-6 (GLA) C 1.0 ^ 0.1 0.9 ^ 0.1 0.9 ^ 0.1 0.9 ^ 0.1
B 0.9 ^ 0.1 1.1 ^ 0.1 1.4* ^ 0.1 1.6* ^ 0.1
20:3n-6 (DGLA) C 0.9 ^ 0.1 0.9 ^ 0.1 0.9 ^ 0.1 0.9 ^ 0.1
B 0.7 ^ 0.1 1.0 ^ 0.1 1.3* ^ 0.1 1.4* ^ 0.1
20:4n-6 (AA) C 5.7 ^ 0.4 5.5 ^ 0.4 6.4 ^ 0.5 6.5 ^ 0.5
B 5.8 ^ 0.4 4.5* ^ 0.6 4.1* ^ 0.4 4.0* ^ 0.4
18:3n-3 C T rT rT rT r
B T rT rT rT r
20:5n-3 C T rT rT rT r
B T rT rT rT r
22:6n-3 C T rT rT rT r
B T rT rT rT r
Details of transmethylation and preparations of fatty acid methyl esters are described in the “Method” section. The number after “n” indicates the number of carbon atoms
from the methyl end of the acyl chain to the nearest double bond. Values are expressed as mg/100mg of PMN total phospholipid fatty acids ^ SEM. Values with * are
signiﬁcantly different (p , 0.05). The letter “Tr” indicates trace.
FIGURE 1 Time-dependent effect of dietary GLA supplement on PMN generation of LTB4. Blood from asthma patients whose diets were either
supplemented with either 2.0g GLA/day as borage oil or placebo corn oil were collected respectively in EDTA at 3-monthly intervals. Neutrophils were
isolated as described in the “Methods” section and then stimulated with Ca
2þ ionophore. The extract was subjected to separation on HPLC to identify
and quantify for LTB4. Patients whose diets were supplemented with GLA-containing borage oil signiﬁcantly (p , 0.05) suppressed Ca
2þ ionophore-
induced PMN generation of LTB4. Results are means ^ SEM. Borage oil group is 19 and corn oil group is 11.
SUPPRESSION OF LEUKOTRIENE B4 17beingthe random effect and “visit number” and “treatment
group” being the ﬁxed effects. For the wheezing score and
rescue usage outcomes, logarithmic transformations were
necessary to meet the assumption of normality of the error.
The data for these outcomes included both estimates of
95% conﬁdence intervals for the medians transformed
back to the original scale (Bland and Altman, 1996) for
each treatment group at each time point. There were no
statistical differences between “wheezing score” and
“rescue usage” when comparing either the borage oil or
corn oil groups. FEV1 could not be transformed to meet
the assumption of normality and therefore the medians and
ranges are presented in Table IV. Once again, there were
no differences between the two groups. Similarly, using an
ANOVA model, wherein all subjects belong to the
“control” or “borage oil” groups throughout (i.e. including
baseline measurements), there were no signiﬁcant
differences in peak ﬂow measurements between groups
for either ﬁxed months ðp ¼ 0:0977Þ or overall
ðp ¼ 0:1415Þ (data not shown). We also note that there
were no signiﬁcant differences in any of the parameters at
any time point between the borage oil and the control
group with respect to the quality of life evaluations (data
not shown). These included evaluation of (1) regular
activities at home and at work; (2) social activities; (3)
outdoor activities; (4) difﬁculty getting to sleep; (5) wake
up during the night; (6) lack of a good night’s sleep; (7)
fatigue; (8) thirst; (9) reduced productivity; (10) tiredness;
(11) poor concentration; (12) headache; (13) worn out;
(14) inconvenience of having to carry tissues or
handkerchief; (15) need to rub nose/eyes; (16) need to
blow nose repeatedly; (17) stuffy/blocked; (18) runny;
(19) sneezing; (20) post-nasal drip; (21) itchy eyes; (22)
watery eyes; (23) sore eyes; (24) swollen eyes; (25)
frustrated; (26) impatient or restless; (27) irritable; (28)
embarrassed by your symptoms.
We also note that there were no differences in exhaled
NO, further conﬁrming the lack of clinical response
(Table V). Our data would suggest that, although we can
cause signiﬁcant changes in biochemical features of the
inﬂammatory response characteristic of asthma, we are
not seeing a signiﬁcant clinical response in clinical
stable asthma.
FIGURE 2 Relationship of elevated incorporation of DGLA into PMN
total phospholipids and decreased PMN generation of LTB4. Blood from
asthma patients whose diets after 12 months were either supplemented
with either 2.0g GLA/day as borage or corn oil were collected,
respectively, in EDTA as described in Fig. 1. The procedures for
identiﬁcation of PMN LTB4 are also described in Fig. 1 and PMN-DGLA
is as described in Table III. (A) Shows relationship of PMN DGLA in
corn and borage oil groups and (B) the relationship of PMN-LTB4 in corn
and borage oil groups.
TABLE IV Quantitation of FEV1
Treatment group FEV1 control FEV1 borage oil
Pre-study Mean 0.90 0.89
Min 0.61 0.69
Median 0.86 0.88
Max 1.15 1.15
Month 0 Mean 0.86 0.86
Min 0.64 0.65
Median 0.84 0.84
Max 1.07 1.10
Month 3 Mean 0.87 0.90
Min 0.58 0.69
Median 0.84 0.88
Max 1.11 1.41
Month 6 Mean 0.87 0.88
Min 0.59 0.51
Median 0.86 0.85
Max 1.16 1.24
Month 9 Mean 0.96 0.90
Min 0.65 0.75
Median 0.97 0.89
Max 1.24 1.09
Month 12 Mean 0.96 0.92
Min 0.67 0.72
Median 0.92 0.90
Max 1.48 1.37
TABLE V Quantitation of exhaled NO (in parts per billion)
Treatment group Corn oil Borage oil
Pre-Study Median estimate 28.7 22.0
95% CI (17.5, 47.1) (15.7, 30.9)
Month 0 Median estimate 32.7 21.1
95% CI (18.8, 57.0) (16.0, 27.9)
Month 3 Median estimate 28.3 23.5
95% CI (17.2, 46.6) (17.4, 31.8)
Month 6 Median estimate 33.6 21.8
95% CI (14.5, 77.7) (15.7, 30.2)
Month 9 Median estimate 37.4 24.2
Median estimate (20.5, 68.2) (17.2, 34.1)
Month 12 Median estimate 40.1 28.6
95% CI (16.7, 96.5) (19.3, 42.4)
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Overall, the results from this 12-month study of dietary
supplementation of GLA-containing borage oil at a dose
of 2.0g GLA per day resulted in a marked in vivo
elevation of DGLA (elongation metabolite of GLA) in
patients PMN phospholipids. This increase also paralleled
reduced PMN phospholipid AA and the suppression of
Ca
2þ ionophore-induced ex vivo PMN generation of
LTB4. Taken together these results are consistent with
reported ﬁndings in the epidermal phospholipids of
normal guinea pigs fed GLA-containing borage oil (Miller
and Ziboh, 1988; Miller et al., 1990). Furthermore, dietary
supplementation with GLA have also been reported to
alter fatty acid proﬁle and eicosanoids in healthy humans
(Ziboh and Fletcher, 1992; Johnson et al., 1997).
Although shorter durations of dietary PUFAs had been
reported, some of the ﬁndings have been conﬂicting. Since
duration of dietary supplementation is essential in a
nutritional study such as this, we were prompted to test our
hypothesis for 12 months. This study underscores the
duration of intake of the dietary supplement prior to the
manifestation of alterations of the altered biochemical
markers that were determined in this study. For instance,
statistically signiﬁcant increase in PMN-DLGA
(elongation product of GLA) was revealed 6 months
after the intake of GLA-containing borage oil implying
that it would be prudent to conduct in vivo studies of this
type for at least 6 months. Interestingly, the increase in
PMN-DGLA continued to manifest itself 12 months after
the intake of the GLA-containing borage oil (data
not shown).
The elevation of PMN-DGLA paralleled the suppres-
sion of Ca
2þ ionophore-induced ex vivo generation
of PMN-LTB4. A typical relationship of PMN-DGLA
increase and PMN-LTB4 suppression after 12 months of
borage oil ingestion is illustrated in Fig. 2. The data
revealed that marked elevation of PMN-DGLA paralleled
statistically signiﬁcant suppression of PMN-LTB4.
The data clearly shows that a relationship exists between
PMN accumulation of DGLA and the suppression
PMN-LTB4. What this study did not show is whether a
dose of 2.0g GLA/day was maximal for generating
maximal PMN-DGLA for greater suppression PMN-
generated LTB4. Whether or not such a direct relation
exists must await future dietary studies.
The mechanism by which dietary GLA dietary
supplementation exerts its in vivo suppression of PMN
generation of LTB4 remains unclear. However, one
possibility is that dietary GLA is converted in vivo by the
elongase enzyme to DGLA. The resulting DGLA is
metabolized via the 15-LOX to 15(S)-hydroxyeicosatrie-
noic acid (15-HETrE). Analysis for 15-HETrE in PMNs
isolated from a small group of patients on dietary borage
oil revealed elevated biosynthesis of PMN-15-HETrE
when compared to the corn oil group (data not shown).
Indeed, the in vitro transformation of DGLA to
15-HETrE has been reported in different systems
(Miller et al., 1988; Iversen et al., 1991; Chilton et al.,
1996; Israel et al., 1996). This metabolite (15-HETrE)
has been reported to inhibit the in vitro transformation of
AA to LTB4 by rat basophilic leukemic (RBL) cells
(Vanderhoek et al., 1980; Miller et al., 1988; Miller et al.,
1991) via 5-LOX. On the other hand, DGLA can also
undergo oxygenation to generate prostaglandin E1
(PGE1) via the cyclooxygenase. This metabolite (PGE1)
has been reported to suppress acute chronic inﬂammation
in adrenalectomized rats (Zurier et al., 1973) and
immune complex vasculitis in rats (Kunkel et al.,
1979), thus, implying that the accumulation of DGLA in
vivo may function to generate two important in vivo
metabolites (15-HETrE and PGE1) that could attenuate
the inﬂammation associated with clinical asthma. Over-
all, our biochemical ﬁndings imply that dietary
supplementation with borage oil containing GLA can
suppress in vivo neutrophil generation of pro-
inﬂammatory LTB4 and therefore can serve to prevent
or attenuate the clinical course of asthma.
Leukotrienes (LT) are a family of potent lipid mediators
of inﬂammation (Borgeat and Samuelsson, 1979; Murphy
et al., 1979) formed by the initial conversion of
arachidonic acid (AA) to leukotriene A4 (LTA4) by the
enzyme 5-LOX. LTA4 is then converted either by LTA4-
hydrolase to leukotriene B4 (LTB4) or by glutathione
transferase to the cysteinyl-leukotrienes (cys-LT), which
include LTC4, LTD4 and LTE4. While LTB4 on the one
hand, exhibits potent chemotactic activity in neutrophils
and eosinophils (Smith et al., 1980), the cys-LTs exhibit
potent bronchoconstrictor activities (Piper et al., 1980),
thus, making the LTs a logical target for the treatment of a
number of inﬂammatory diseases including asthma.
Speciﬁc binding sites (receptors) for the cys-LTs have
been identiﬁed in guinea pig and in human lung
parenchyma (Kuehl et al., 1984). In human bronchopro-
vocation studies, leukotriene D4 (LTD4)a c t sa sa
bronchospastic agent (Weiss et al., 1983; Bisgaard et al.,
1985; Davidson et al., 1987). More recently, a selective
LTD4/LTE4-receptor antagonist has been found to result
in signiﬁcant improvement in FEV-1, wheezing and
breathlessness (Cloud et al., 1989). Importantly, Zileuton,
a 5-LOX inhibitor, has been reported to attenuate asthma
symptoms and to exert signiﬁcant reduction in the
incidence of exacerbations in patients with mild to
moderate asthma (Israel et al.,1996; Liu et al., 1996). This
promising effect is nonetheless dampened by reported
elevation of liver enzymes in a sub-group of patients.
Dietary supplementation of GLA to patients with RA
had clearly been reported to attenuate the signs and
symptoms of inﬂammatory RA disease activity. Further-
more, dietary ingestion of GLA by normal human
individuals did result in the suppression of the ability of
their Ca
2þ ionophore activated PMNs to generate LTB4
(Ziboh and Fletcher, 1992). Taken together, because
15-LOX metabolite of GLA/DGLA (15-HETrE) had
been reported to inhibit LTB4 generation by RBL-I cells
in vitro (Vanderhoek et al., 1980), we in this study
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GLA-containing oil (borage oil) to mild and moderate
asthmatic patients would result in elevated DGLA in the
patients PMNs and result in the suppression of the
asthmatic PMNs to biosynthesize LTB4.
However, the data from our borage oil study are both
biologically and clinically important. Although we have
clearly demonstrated a meaningful change in leukotrienes,
we have demonstrated that such a change is not
accompanied by an improvement in asthma scores. This
result has important speciﬁc implications for our under-
standing of biological mediators and asthma but also has
generic implications for other inﬂammatory processes that
have hypothesized that changes in leukotrienes mediated
by diet will have clinical implications. Since asthma is a
multifactorial disease process, it is likely that other
contributory mediators to the pathogenesis of asthma were
not responsive to inhibition of the 5-LOX pathway.
Alternatively, the dose of gamma-linolenate (2g/day)
given to patients with mild to moderate asthma maybe
inadequate to strongly inhibit all 5-LOX metabolites and
thereby exert amelioration of the asthma. The power
calculations that follow emphasize this point. The required
pieces of information in any “power calculation” are the
“detectable difference of interest”, the “person-to-person”
(or “between subject”) and “within person, between
observation” (or “residual”) variations, and the desired
power and size (often called “alpha level” or “level or
signiﬁcance”). As a rule, 80 and 5% are used for power
and size, respectively, and that was used herein.
Regarding the “detectable difference of interest”, we
usedthesmallest difference betweenthegroups thatwould
be frequently referred to as “clinical” or “practical
signiﬁcance”. This is because, if the actual effect is larger,
the statistical tests will havegreater-than-stated power (i.e.
willbeeasiertodetect);but,iftheactualeffectissmaller,it
is less likely than the stated power that there will be
statistical signiﬁcance and these small differences would
not be of clinical interest. As is always the case, a larger
differencebetweenthegroupsiseasiertodetect(i.e.would
require a smaller sample size, all else being equal).
The estimates of variation come from our data sets
and thus should be better than predictors prior to our
study. Often, it is a good idea to increase the estimates
of variation slightly to be conservative, as it is better to
get a larger sample than is necessary than to have too
small of a sample to be able to distinguish between the
levels. We did not use that approach here, though.
Rather we used exactly the variances observed in the
data set. The reason that the person-to-person variation
estimate is necessary is to allow overall comparisons
between the two groups in the mixed model ANOVA
that has been and will be used in the analysis for the
data sets. To compare the two groups within any speciﬁc
time period, however, the “within person, between
observations” variations are used. Since baseline
measurements are taken from both groups, the contrasts
of greater interest will almost certainly be between
the groups for a ﬁxed time-point. For the clinical
outcome “wheeze score”, we used a logarithmic
transformation in the analysis on the earlier data set.
We added 1 to every observation before taking the
natural logarithm of the value so as to include zeroes, a
25% decrease from the placebo group would actually be
a difference of about 0.196 at the baseline means.
Without the addition of 1 to the values, a 25% decrease
from the placebo group is 0.2877, which is the value we
used in the power calculations. Although one can
propose the use of higher doses of borage oil for longer
duration, the conclusion herein is that a signiﬁcant
biochemical alteration does not lead to a discernible
clinical response. Asthma is clearly a multi-factorial
process and dietary supplements, at least as used herein,
do not appear to have clinical beneﬁt.
Mixed model ANOVA methods were used to model
the outcomes “PEF”, “wheezing score” and “rescue
usage”, with the subjects being the random effect and
“visit number” and “treatment group” being the ﬁxed
effects. For the wheezing score and rescue usage
outcomes, logarithmic transformation were necessary to
meet the assumption of normality of the error. The tables
for these outcomes present estimates and 95%
conﬁdence intervals for the medians transformed back
to the original scale (Bland and Altman, 1996) for each
treatment group at each time point.
Overall, data from this study does demonstrate that
dietary ingestion of gamma-linolenate as borage oil
does elevate PMN DGLA and its 5-LOX metabolite
5-HETrE which parallel suppression of PMN LTB4.
Although our data did not reveal suppression of
measured clinical scores, which likely may be due to
other mediators contributing to the asthma (a multi-
factorial disease) or alternatively, the dose of 2.0g GLA
used may be inadequate to attenuate the multitude
asthma processes. Nonetheless, these ﬁndings are
interesting and warrant further explorations into the
role of higher doses of GLA, LTB4 and other possible
mediators in asthma.
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